Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A promising new therapy for inflammatory bowel disease is turning heads. Duvakitug, an anti-TL1A monoclonal antibody, significantly outperformed placebo in achieving endoscopic response in Crohn's disease and clinical remission in ulcerative colitis at 14 weeks in the phase 2b RELIEVE UCCD trial. Encouragingly, results held up in both patients new to advanced therapy and those who had already tried other treatments.
A promising new therapy for inflammatory bowel disease is turning heads. Duvakitug, an investigational anti-TL1A monoclonal antibody developed by Teva Pharmaceuticals and Sanofi, delivered "clinically meaningful" results against placebo in the phase 2b RELIEVE UCCD trial — a multicenter study spanning 163 sites across 19 countries. The trial used an innovative "basket" design, running both a Crohn's disease (CD) and ulcerative colitis (UC) cohort under a single master protocol.
The drug targets the TL1A pathway, which is thought to drive both inflammation and fibrosis in IBD — two processes that current therapies often struggle to address simultaneously. Results were consistent across patients who were new to advanced therapy and those who had already cycled through other treatments, a particularly encouraging sign for a patient population with limited options.
By the Numbers:
Why it matters: Many IBD patients lose response to existing therapies over time, leaving them in a cycle of switching treatments. Duvakitug's dual action on inflammation and fibrosis — and its efficacy even in treatment-experienced patients — could represent a meaningful new option. Phase 3 trials are already underway.
